Insights into Companion Diagnostics During the COVID-19 Pandemic - 2020 Market Study
Dublin, Oct. 21, 2020 (GLOBE NEWSWIRE) -- The "Companion Diagnostics in the COVID-19 Era: Market Analysis and Opportunities" report has been added to ResearchAndMarkets.com's offering.
This report provides a comprehensive market analysis and business planning tool for the market for tests that are aligned with pharmaceutical treatment. Especially in oncology, companion diagnostics are rising to the forefront of pharmaceutical development and treatment.
Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics can also decrease costs by identifying the patient population that will most likely benefit from the therapy and ruling out therapies that are not likely to be effective. But what is the market for these therapy/test combinations? And who is winning in the quest to develop them? How much will the market be in the future? What specific drugs are seeing test product approvals, and sales of those products? How has COVID-19 impacted the sector? This resource provides answers to these questions and more.
As part of its coverage, this report provides:
Sense of the Market
COVID-19 impacts on Companion Diagnostics- Where are We Now?
Top Performing Targeted Therapies in Oncology with CDx Component, based on 2019 Sales
FDA Cleared/Approved Companion Diagnostic Tests, 2010-2020
Global In Vitro Companion Diagnostic (CDx) Market, 2019-2024 ($ millions)
Global In Vitro Companion Diagnostic (CDx) Market by Region
Regulatory Picture
FDA changes in CDx regulation: Shifting to Drug Classification CDx Labeling
FDA Approved Companion Diagnostics Labeled for Identifying Patients with NSCLC whose Tumors have EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution - Mutations and the Associated Therapeutic Products Listed on the Companion Diagnostic Labels
EU Companion Diagnostic Regulation Guidance
Competitive Analysis
Selected Companies offering Companion and Complementary Diagnostics for Autoimmune Disorder Therapies
Selected Companies offering Companion and Complementary Diagnostics for Cardiology and Hematology Therapies
Selected Companies offering Companion and Complementary Diagnostics for Infectious Disease Therapies Human Leukocyte Antigen (HLA) and COVID-19
Selected Companies offering Companion and Complementary Diagnostics for Neurology Therapies, including Psychiatry
Deep Dives into the CDx Market
Estimated Value of Other (non-oncology) Companion Diagnostics by Cancer Type, Distribution 2019 (%)
Distribution of Commercialized Targeted Therapies Revenues, using CDx by, Drug Class (Kinase Inhibitor, Monoclonal Antibody, Poly ADP Ribose Polymerase Inhibitor, Apoptosis Inducer, PI3K Inhibitor, Other)
Market Value of Commercialized Targeted Therapies compared to Companion Diagnostic Market Value, 2015-2019 Dx Approvals (PMAs) by Technique, 2010-2020
FDA Approved Companion Dx by Technique (IHC, PCR, FISH, NGS) and Year
Global CDx Market by Region (US, EU, Asia, ROW), 2019-2024
The emergence of new technology has opened doors for companion diagnostic research, discovery, development and commercialization. This has resulted in a huge increase in exploratory studies, diagnostic developments, and clinical usefulness in the pursuit of personalized medicine. Companion diagnostics and biomarkers provide insight into understanding disease processes and ways that medicines can work to counteract the disease. Novel biomarkers and subsequent companion diagnostics have the potential to transform the current healthcare model from a one-size-fits-all approach to a personalized approach
Companies Covered:
Abbott Diagnostics
Agilent Technologies Inc./Dako
Biocartis
Foundation Medicine, Inc.
Guardant Health, Inc.
Illumina, Inc.
Myriad Genetics, Inc.
Neogenomics
Qiagen N.V.
Roche Diagnostics
Thermo Fisher Scientific Inc.
The entire medical industry is in transition. The number of elderly individuals is increasing, leading to a higher demand for new and better medical technology products. However, governments are trying to limit and lower public health care costs by instituting restrictions and in a more recent example, a planned health system reform in the United States. The main goals of this reform are cost savings and increased efficiency. This is where companion diagnostics can be important to the delivery of care.
This report provides a tool for understanding that market and is one of the analyst's most popular report topics.
Key Topics Covered:
Chapter 1: Executive Summary and COVID-19 Developments
Overview
Definitions of Companion Diagnostics and Personalized Medicine Used in This Report
Terms Used in Companion Diagnostics and Personalized Medicine
COVID-19 CDx Test Volume Impact: Minimal Ongoing Significant Disruptions
Biomarker Development: COVID-19 Focus
Addressing COVID-19 with a Personalized Medicine Approach
Scope and Methodology
Market Summary
Chapter 2: Introduction to Personalized Healthcare and Companion Diagnostics
Overview
Regulatory Changes
FDA changes in CDx regulation: Shifting to Drug Classification CDx Labeling
EU Companion Diagnostic Regulation Guidance
The FDA and Identifying Pharmacogenetic Associations
Reimbursement Breakthroughs and Challenges
Next Generation Sequencing Coverage
CDx Approvals: United States FDA
The Market for Targeted Therapies: Oncology
Targeted Therapies in Development
Development in NGS for CDx
Next Generation Sequencing or Massively Parallel Sequencing in Cancer Diagnostics
The Evolving Opportunity in Japan
Disease Profiles in CDx Markets
Cancer
Cardiovascular Disease
Selected Blood Disorders
Autoimmune and Immunological Diseases
Infectious Diseases
Chapter 3: Companion Dx Market Analysis
Market Overview
Biomarkers in Therapeutic Labeling
Companion Diagnostics in Oncology
Market Review and Outlook
Companion Diagnostics in Other Diseases
Overview
Autoimmune Disorders
Cardiology and Hematology
Infectious Disease
Human Leukocyte Antigen (HLA) and COVID-19
Neurology
Market Review and Outlook
Diagnostic Techniques
Market Overview
Immunohistochemistry (IHC)
In Situ Hybridization
Nucleic Acid Amplification Technologies
Sequencing Technologies
Flow Cytometry
Microarrays
Mass Spectrometry
Liquid Biopsies - Circulating Tumor Cells and Circulating Tumor DNA (Cell Free DNA)
Analysis of Gene Expression Patterns (Gene Signatures)
Information Technology
Regional Market Review
U.S. Market
European Market
Reimbursement in European Markets
Japanese Market
Chinese Market
Rest of World Market
Chapter 4: Competitive Analysis
Competitive Landscape
Alliances, Acquisitions and Collaborations
Competitor Analysis
CDx Product Mix: Leading IVD Companies
Chapter 5: Market Participant Profiles
Profile Scope
Abbott Diagnostics
Company Overview
Financial Review
Product Overview: Companion Dx
Agilent Technologies Inc./Dako
Company Overview
Financial Review
Product Overview: Companion Dx
Biocartis
Company Overview
Financial Review
Product Overview: Companion Dx
Foundation Medicine, Inc.
Company Overview
Financial Review
Product Overview: Companion Dx
Guardant Health, Inc.
Company Overview
Financial Review
Product Overview: Companion Dx
Illumina, Inc.
Company Overview
Financial Review
Product Overview: Companion Dx
Myriad Genetics, Inc.
Company Overview
Financial Review
Product Overview: Companion Dx
NeoGenomics
Company Overview
Financial Review
Product Overview: Companion Dx
QIAGEN N.V.
Company Overview
Financial Review
Product Overview: Companion Dx
Roche Diagnostics
Company Overview
Financial Review
Company Overview: Companion Dx
Thermo Fisher Scientific Inc.
Company Overview
Financial Review
Product Overview: Companion Dx
For more information about this report visit https://www.researchandmarkets.com/r/t39a08
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900